Immunome Stock Target Price
| IMNM Stock | USD 10.59 0.07 0.67% |
Fundamental analysis of Immunome allows traders to better anticipate movements in Immunome's stock price by examining its financial health and performance throughout various phases of its business cycle.
Immunome | Target Price | Build AI portfolio with Immunome Stock |
Immunome Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunome's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunome could also be used in its relative valuation, which is a method of valuing Immunome by comparing valuation metrics of similar companies.Immunome is currently under evaluation in target price category among its peers.
Immunome Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunome from analyzing Immunome's financial statements. These drivers represent accounts that assess Immunome's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunome's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 97.9M | 149.5M | 26.8M | 212.3M | 622.8M | 653.9M | |
| Enterprise Value | 58.7M | 100.6M | 6.8M | 115.3M | 484.2M | 508.4M |
Immunome ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunome's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunome's managers, analysts, and investors.Environmental | Governance | Social |
Immunome Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (15.26) % | ||||
| Current Valuation | 610.65 M | ||||
| Shares Outstanding | 87.01 M | ||||
| Shares Owned By Insiders | 11.47 % | ||||
| Shares Owned By Institutions | 84.04 % | ||||
| Number Of Shares Shorted | 14.2 M | ||||
| Price To Book | 3.01 X | ||||
| Price To Sales | 84.24 X | ||||
| Revenue | 9.04 M | ||||
| Gross Profit | (140.11 M) | ||||
| EBITDA | (151.35 M) | ||||
| Net Income | (292.96 M) | ||||
| Cash And Equivalents | 34.65 M | ||||
| Cash Per Share | 2.86 X | ||||
| Total Debt | 4.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 3.53 X | ||||
| Cash Flow From Operations | (110.79 M) | ||||
| Short Ratio | 12.58 X | ||||
| Earnings Per Share | (3.01) X | ||||
| Target Price | 24.5 | ||||
| Number Of Employees | 131 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 921.46 M | ||||
| Total Asset | 240.24 M | ||||
| Retained Earnings | (515.77 M) | ||||
| Working Capital | 167.03 M | ||||
| Net Asset | 240.24 M |
About Immunome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunome's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunome based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Immunome Piotroski F Score and Immunome Altman Z Score analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.01) | Revenue Per Share | Quarterly Revenue Growth 1.844 | Return On Assets | Return On Equity |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.